We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+5.81%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$735M
AUM Growth
+$91.2M
Cap. Flow
+$63.4M
Cap. Flow %
8.63%
Top 10 Hldgs %
24.07%
Holding
118
New
17
Increased
44
Reduced
5
Closed
14

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$14.4M
2
SYNA icon
Synaptics
SYNA
+$9.97M
3
DATA
Tableau Software, Inc.
DATA
+$9.41M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.8M
5
AKBA icon
Akebia Therapeutics
AKBA
+$4M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$4.68M
2
SJM icon
J.M. Smucker
SJM
+$4.51M
3
NOV icon
NOV
NOV
+$3.7M
4
PCYC
PHARMACYCLICS INC
PCYC
+$2.7M
5
ECYT
Endocyte, Inc. Common Stock
ECYT
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 26.56%
2 Technology 14.37%
3 Consumer Discretionary 13.18%
4 Industrials 9.24%
5 Materials 6.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPLN
51
Openlane
OPLN
$4.29B
$6.78M 0.92%
561,689
– –
FC icon
52
Franklin Covey
FC
$243M
$6.35M 0.86%
315,600
– –
PWR icon
53
Quanta Services
PWR
$98.7B
$6.32M 0.86%
182,800
+48,800
+36% +$1.69M
TSLA icon
54
Tesla
TSLA
$1.22T
$6.31M 0.86%
394,500
– –
SCTY
55
DELISTED
SolarCity Corporation
SCTY
$6.28M 0.85%
89,000
-25,000
-22% -$1.4M
AZPN
56
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$5.96M 0.81%
128,500
– –
LUMO
57
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$5.73M 0.78%
23,967
– –
AGTC
58
DELISTED
Applied Genetic Technologies Corporation
AGTC
$4.75M 0.65%
+205,500
New +$3.62M
CLDX icon
59
Celldex Therapeutics
CLDX
$3.02B
$4.71M 0.64%
19,247
– –
AKBA icon
60
Akebia Therapeutics
AKBA
$362M
$4.62M 0.63%
+166,200
New +$4M
SZYM
61
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
$4.53M 0.62%
384,400
+20,400
+6% +$217K
TTPH
62
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$4.06M 0.55%
15,045
– –
CGNX icon
63
Cognex
CGNX
$10.4B
$3.84M 0.52%
+200,000
New +$3.53M
MGNX icon
64
MacroGenics
MGNX
$240M
$3.58M 0.49%
164,800
+108,600
+193% +$2.28M
BLUE
65
DELISTED
bluebird bio
BLUE
$2.97M 0.4%
5,937
+919
+18% +$295K
ATRC icon
66
AtriCure
ATRC
$2.04B
$2.8M 0.38%
152,300
+8,500
+6% +$141K
SLXP
67
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$2.69M 0.37%
21,800
+1,300
+6% +$144K
GWPH
68
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.68M 0.36%
+25,000
New +$1.74M
VCYT icon
69
Veracyte
VCYT
$4.77B
$2.65M 0.36%
+154,700
New +$2.23M
SUPN icon
70
Supernus Pharmaceuticals
SUPN
$2.65B
$2.63M 0.36%
240,600
+25,100
+12% +$224K
RARE icon
71
Ultragenyx Pharmaceutical
RARE
$2.56B
$2.36M 0.32%
+52,600
New +$2.17M
RGEN icon
72
Repligen
RGEN
$8.1B
$2.27M 0.31%
99,400
+45,700
+85% +$814K
XLRN
73
DELISTED
Acceleron Pharma
XLRN
$2.11M 0.29%
+62,100
New +$2.08M
CBST
74
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$2.02M 0.28%
29,000
+1,600
+6% +$109K
CERN
75
DELISTED
Cerner Corp
CERN
$2.01M 0.27%
38,900
+2,100
+6% +$110K
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Eventide Asset Management held 118 positions worth $735M, up 14% from $644M the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management deployed $63.4M of net new capital in Q2 2014, opening 17 new positions and adding to 44 existing holdings. Its largest new stake was Celgene Corp: 190,000 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 24% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was PHARMACYCLICS INC, an estimated $2.7M trimmed.

  • Eventide Asset Management's largest Q2 2014 buy was Celgene Corp: 190,000 shares worth $16.3M.
  • Eventide Asset Management added most to Acadia Pharmaceuticals in Q2 2014, an estimated $4.8M increase.
  • Eventide Asset Management's biggest Q2 2014 reduction was PHARMACYCLICS INC, cutting an estimated $2.7M.
  • Eventide Asset Management fully exited Puma Biotechnology in Q2 2014, selling an estimated $4.68M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $735M portfolio in Q2 2014.
  • Eventide Asset Management opened 17 new positions and closed 14 in Q2 2014.
  • Eventide Asset Management's portfolio value rose 14% quarter-over-quarter to $735M.

Based on Eventide Asset Management's 13F filing for Q2 2014, filed 14 Aug 2014.